ClinicalTrials.gg
CompletedNCT02001688Updated Jan 18, 2020Results posted

Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"

A Phase 2 interventional study of Kamada-AAT for Inhalation, 80mg and Placebo in Alpha-1 Antitrypsin Deficiency, sponsored by Kamada, Ltd.. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-01-18.

Sponsored by Kamada, Ltd. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States — 17 open to participants now, 22 under way, 5 of them phase 3. alpha 1-Antitrypsin Deficiency · United States.

Enrollment
25th of 55
36 · median 30
Started
2014
with 2 others
Phase 2
20 of 81
none open now
Registered
37th of 81
by date

Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, this one is the 25th largest by enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2014, is one of 20 in phase 2, and was the 37th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

17 of the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, or all of them as a file.
02

Study summary

To evaluate different doses of "Kamada-AAT for Inhalation" on the levels of alpha 1-proteinase inhibitor and other analytes in epithelial lining fluid (ELF) and serum and to assess the safety of the treatment in subjects with AAT Deficiency.

03

Conditions studied

  • Alpha-1 Antitrypsin Deficiency
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients between 18 and 65 years of age (inclusive).
  • Able and willing to sign .
  • Males, and non-pregnant, non-lactating females whose screening pregnancy test is negative and who are using methods deemed reliable by the investigator or who are or surgically sterilized.
  • Diagnosis of alpha1-antitrypsin deficiency [only individuals with a ZZ or Z null classification].
  • (FEV1) ≥ 50% of predicted post bronchodilator
  • No respiratory exacerbations within 6 weeks of baseline. Subjects can be re-screened if exacerbations exist at the time of enrollment.
  • No signs of chronic and/or acute Hepatitis A, , , infection and Parvovirus B19, by NAT (for Parvovirus B19, nucleic acid testing (NAT) result must be \< 10\^4 IU/mL).
  • No significant abnormalities in serum hematology, serum chemistry, serum inflammatory / immunogenic markers and urinalysis.
  • No significant abnormalities in .
  • Not on intravenous augmentation therapy for at least 8 weeks prior to initial dosing with study drug/placebo and willing to forego intravenous augmentation therapy for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • intercurrent illnesses (except for respiratory or liver disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. Patients with well-controlled, chronic diseases could possibly be included after consultation with the treating physician and the sponsor.
  • History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products.
  • History of life threatening transfusion reactions.
  • History of lung transplant.
  • Current or previous (up to 8 weeks from baseline) use of AAT augmentation therapy or by any other route
  • Current use of oral or parenteral in doses exceeding 10mg of prednisone daily or equivalent generics (substance and dose).
  • Any lung surgery within the past two years.
  • On any thoracic surgery waiting list.
  • Active smoking during the last 12 months from screening date.
  • Pregnancy or lactation.
  • Woman of not taking adequate deemed reliable by the investigator.
  • Presence of psychiatric/ mental disorder or any other medical disorder which might impair the patient's ability to give or to comply with the requirements of the study protocol.
  • Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs.
  • Immunoglobulin A (IgA) Deficiency.
  • Inability to undergo bronchoscopy.
  • Allergy to lidocaine or any other medicines used in the bronchoscopy process
  • Exacerbation of (COPD) in the previous 6 weeks.
  • Participation in another clinical trial involving medication or interventional treatment within 30 days prior to baseline visit.
  • Participation in observational clinical trial which involves any invasive procedure scheduled to occur during the AAT inhaled study period. If participating in an observational clinical trial that already completed all diagnostic procedures (e.g. liver ), any adverse events (AEs) experienced must have returned to baseline within 30 days prior to baseline visit.
  • Inability to attend scheduled clinic visits and/or comply with the study protocol.
  • Any other factor that, in the opinion of the investigator, would prevent the patient form complying with the requirements of the protocol.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Kamada-AAT for Inhalation, 80mg

    Daily inhalation of Kamada-AAT for Inhalation, 80mg

    Drug: Kamada-AAT for Inhalation, 80mg

  • Placebo comparator
    Placebo

    Placebo administered by inhalation daily

    Drug: Placebo

  • Experimental
    Kamada-AAT for Inhalation, 160mg

    Daily inhalation of Kamada-AAT for Inhalation, 160mg

    Drug: Kamada-AAT for Inhalation, 160mg

Interventions

  • DrugKamada-AAT for Inhalation, 80mg
  • DrugPlacebo
  • DrugKamada-AAT for Inhalation, 160mg
06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Concentration of Antigenic Alpha-1 Antitrypsin (AAT) in the Lung Epithelial Lining Fluid (ELF)

    Patients underwent bronchoalveolar lavage (BAL) prior to initiation of drug and then again after 3 months. Concentration of AAT in the BAL was measured by an enzyme linked immunosorbent assay (ELISA) specific for the normal form of AAT (piM). Urea was also measured in order to determine the dilution factor of the BAL fluid and calculate the concentration of AAT in the ELF.

    Time frame: 12 weeks from initiation of study drug

  2. Change From Baseline to 12 Weeks in the Concentration of Functional AAT (Alpha-1 Antitrypsin) in ELF

    ITT population with baseline and 12 week values. Patients underwent bronchoalveolar lavage (BAL) prior to initiation of drug and then again after 3 months. Concentration of AAT in the BAL was measured by an antineutrophil elastase capacity (ANEC) assay. Urea was also measured in order to determine the dilution factor of the BAL fluid and calculate the concentration of AAT in the ELF.

    Time frame: 12 weeks from initiation of study drug

Secondary outcomes

  1. Change From Baseline in Levels of M Specific AAT in Plasma (PiM)

    Intention to treat (ITT) population with baseline and 12 week values.The median change from baseline to Week 12 in the levels of M-specific AAT (piM) in plasma was measured using a specific ELISA assay for M-specific AAT (piM)

    Time frame: 12 weeks from initiation of study drug

  2. Change From Baseline in AAT-neutrophil Elastase (NE) Complexes in ELF

    Patients underwent a BAL procedure at baseline and 12 weeks and the fluid was analyzed to calculate the change from baseline in the concentration of complexes between AAT and neutrophil elastase in the ELF

    Time frame: 12 weeks from initiation of study drug

07

Results

Posted Jan 18, 2020

Participant flow

There were 2 clinical sites. At each site, 18 subjects were recruited and randomized 2:1 to receive either "Kamada-AAT for Inhalation" 80 mg/day (site 1) or 160 mg/day (site 2) or placebo. This gave a total of 12 patients randomized to receive 80 mg/day active drug, 12 patients randomized to receive 160 mg/day active drug, and 12 patients placebo

Participant flow — Overall Study
MilestoneKamada-AAT for Inhalation, 80mgKamada-AAT for Inhalation, 160mgPlacebo
Started121212
Completed121111
Not completed011
Withdrew: Withdrawal by subject001
Withdrew: Adverse event010

Outcome measures

PrimaryChange From Baseline in the Concentration of Antigenic Alpha-1 Antitrypsin (AAT) in the Lung Epithelial Lining Fluid (ELF)

Patients underwent bronchoalveolar lavage (BAL) prior to initiation of drug and then again after 3 months. Concentration of AAT in the BAL was measured by an enzyme linked immunosorbent assay (ELISA) specific for the normal form of AAT (piM). Urea was also measured in order to determine the dilution factor of the BAL fluid and calculate the concentration of AAT in the ELF.

Time frame:
12 weeks from initiation of study drug
Reported as:
Median · nmol
Change From Baseline in the Concentration of Antigenic Alpha-1 Antitrypsin (AAT) in the Lung Epithelial Lining Fluid (ELF)
nmolKamada-AAT for Inhalation, 80mgKamada-AAT for Inhalation, 160mgPlacebo
Change From Baseline in the Concentration of Antigenic Alpha-1 Antitrypsin (AAT) in the Lung Epithelial Lining Fluid (ELF)4551.023 (2587 to 6835.6)13454.772 (1020.7 to 70907.95)-27.15 (-103.6 to 196.7)
Statistical analysis
  • Kamada-AAT for Inhalation, 80mg vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0005 (One-sided test was used for antigenic and functional AAT levels to maintain overall 2.5% level of significance)
  • Kamada-AAT for Inhalation, 160mg vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.020One-sided test was used for antigenic and functional AAT levels to maintain overall 2.5% level of significance
  • Kamada-AAT for Inhalation, 80mg vs Kamada-AAT for Inhalation, 160mg · Wilcoxon (Mann-Whitney) · p = 0.0192One-sided test was used for antigenic and functional AAT levels to maintain overall 2.5% level of significance
PrimaryChange From Baseline to 12 Weeks in the Concentration of Functional AAT (Alpha-1 Antitrypsin) in ELF

ITT population with baseline and 12 week values. Patients underwent bronchoalveolar lavage (BAL) prior to initiation of drug and then again after 3 months. Concentration of AAT in the BAL was measured by an antineutrophil elastase capacity (ANEC) assay. Urea was also measured in order to determine the dilution factor of the BAL fluid and calculate the concentration of AAT in the ELF.

Time frame:
12 weeks from initiation of study drug
Reported as:
Median · nmol
Change From Baseline to 12 Weeks in the Concentration of Functional AAT (Alpha-1 Antitrypsin) in ELF
nmolKamada-AAT for Inhalation, 80mgKamada-AAT for Inhalation, 160mgPlacebo
Change From Baseline to 12 Weeks in the Concentration of Functional AAT (Alpha-1 Antitrypsin) in ELF2766.343 (840.9 to 3800.3)3557.563 (1582.8 to 10673.2)5.831 (-1032 to 884.3)
Statistical analysis
  • Kamada-AAT for Inhalation, 80mg vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0005 (One-sided test was used for antigenic and functional AAT levels to maintain overall 2.5% level of significance)p-value of Stratified Wilcoxon test
  • Kamada-AAT for Inhalation, 160mg vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0193One-sided test was used for antigenic and functional AAT levels to maintain overall 2.5% level of significance
  • Kamada-AAT for Inhalation, 80mg vs Kamada-AAT for Inhalation, 160mg · Wilcoxon (Mann-Whitney) · p = 0.2485One-sided test was used for antigenic and functional AAT levels to maintain overall 2.5% level of significance
SecondaryChange From Baseline in Levels of M Specific AAT in Plasma (PiM)

Intention to treat (ITT) population with baseline and 12 week values.The median change from baseline to Week 12 in the levels of M-specific AAT (piM) in plasma was measured using a specific ELISA assay for M-specific AAT (piM)

Time frame:
12 weeks from initiation of study drug
Reported as:
Median · nM
Change From Baseline in Levels of M Specific AAT in Plasma (PiM)
nMKamada-AAT for Inhalation, 80mgKamada-AAT for Inhalation, 160mgPlacebo
Change From Baseline in Levels of M Specific AAT in Plasma (PiM)113.17 (56.3 to 158.1)90.73 (37.3 to 369.7)-4.02 (-9.8 to 4.9)
Statistical analysis
  • Kamada-AAT for Inhalation, 80mg vs Kamada-AAT for Inhalation, 160mg vs Placebo · Kruskal-Wallis · p = <0.0001p-value of Kruskal-Wallis test (3 groups: Kamada-AAT for Inhalation, 80mg,Kamada-AAT for Inhalation, 160mg and placebo)
SecondaryChange From Baseline in AAT-neutrophil Elastase (NE) Complexes in ELF

Patients underwent a BAL procedure at baseline and 12 weeks and the fluid was analyzed to calculate the change from baseline in the concentration of complexes between AAT and neutrophil elastase in the ELF

Time frame:
12 weeks from initiation of study drug
Reported as:
Median · nM
Change From Baseline in AAT-neutrophil Elastase (NE) Complexes in ELF
nMKamada-AAT for Inhalation, 80mgKamada-AAT for Inhalation, 160mgPlacebo
Change From Baseline in AAT-neutrophil Elastase (NE) Complexes in ELF38.71 (8.4 to 66.8)46.225 (17.6 to 436.3)0 (-2 to 1.3)
Statistical analysis
  • Kamada-AAT for Inhalation, 80mg vs Kamada-AAT for Inhalation, 160mg · Kruskal-Wallis · p = <0.0001p-value of Kruskal-Wallis test (3 groups: Kamada-AAT for Inhalation, 80mg, Kamada-AAT for Inhalation, 160mg and placebo)

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Kamada-AAT for Inhalation, 80mg0/12 (0%)0/12 (0%)10/12 (83.3%)
Kamada-AAT for Inhalation, 160mg0/12 (0%)1/12 (8.3%)8/12 (66.7%)
Placebo0/12 (0%)0/12 (0%)7/12 (58.3%)
Most frequent serious events
Most frequent serious events
EventKamada-AAT for Inhalation, 80mgKamada-AAT for Inhalation, 160mgPlacebo
PneumoniaInfections and infestations0/121/120/12
Most frequent other events
Showing 10 of 49
Most frequent other events
EventKamada-AAT for Inhalation, 80mgKamada-AAT for Inhalation, 160mgPlacebo
CoughRespiratory, thoracic and mediastinal disorders4/121/123/12
Gastrooesophageal reflux diseaseGastrointestinal disorders0/122/120/12
PyrexiaGeneral disorders2/120/120/12
NasopharyngitisInfections and infestations2/122/122/12
Upper respiratory tract infectionInfections and infestations2/121/121/12
HeadacheNervous system disorders2/120/121/12
BronchospasmRespiratory, thoracic and mediastinal disorders0/122/120/12
Pulmonary congestionRespiratory, thoracic and mediastinal disorders0/120/122/12
RhinorrhoeaRespiratory, thoracic and mediastinal disorders1/122/120/12
Lip swellingGastrointestinal disorders0/120/121/12

Baseline characteristics

ITT population

Age, Continuous
Age, Continuous(years)Kamada-AAT for Inhalation, 80mgKamada-AAT for Inhalation, 160mgPlaceboTotal
Mean55.5 ± 8.6955.3 ± 10.1356.3 ± 4.7755.7 ± 7.96
Sex: Female, Male
Sex: Female, Male(Participants)Kamada-AAT for Inhalation, 80mgKamada-AAT for Inhalation, 160mgPlaceboTotal
Female97824
Male35412
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Kamada-AAT for Inhalation, 80mgKamada-AAT for Inhalation, 160mgPlaceboTotal
White Non-Hispanic12121236
Region of Enrollment
Region of Enrollment(participants)Kamada-AAT for Inhalation, 80mgKamada-AAT for Inhalation, 160mgPlaceboTotal
United States12121212
BMI
BMI(kg/m^2)Kamada-AAT for Inhalation, 80mgKamada-AAT for Inhalation, 160mgPlaceboTotal
Mean30.0 ± 4.328.3 ± 8.325.8 ± 4.528.0 ± 6.1
%Predicted forced expiratory volume in one second (FEV1)
%Predicted forced expiratory volume in one second (FEV1)(%)Kamada-AAT for Inhalation, 80mgKamada-AAT for Inhalation, 160mgPlaceboTotal
Mean81.7 ± 17.973.2 ± 20.178.1 ± 20.077.6 ± 19.1
08

Study locations

2 sites
  • University of Florida, Pulmonary, Critical Care & Sleep Medicine
    Gainesville, Florida 32610, United States
  • The University of Texas Health Science Center at Tyler Center for Clinical Research
    Tyler, Texas 75708, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Feb 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2020, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2013
First posted
Dec 5, 2013
Start
Apr 2014
Primary completionActual
Feb 2016
CompletionActual
May 2016
Results first posted
Jan 18, 2020
Last update
Jan 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02001688
Lead sponsor
Kamada, Ltd.
Responsible party
Sponsor
First posted
Dec 5, 2013
Start date
Apr 2014
Primary completion
Feb 2016
Completion
May 2016
Results posted
Jan 18, 2020
Last update
Jan 18, 2020
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion